The global Innovative Biologics and Biosimilars market was valued at 403010 million in 2024 and is projected to reach US$ 744830 million by 2031, at a CAGR of 9.4% during the forecast period.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Innovative Biologics and Biosimilars companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Innovative Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Innovative Biologics and Biosimilars. This report contains market size and forecasts of Innovative Biologics and Biosimilars in global, including the following market information:
Global Innovative Biologics and Biosimilars market revenue, 2020-2025, 2026-2031, ($ millions)
Global top five Innovative Biologics and Biosimilars companies in 2024 (%)
Total Market by Segment:
Global Innovative Biologics and Biosimilars market, by Type, 2020-2025, 2026-2031 ($ millions)
Global Innovative Biologics and Biosimilars market segment percentages, by Type, 2024 (%)
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Global Innovative Biologics and Biosimilars market, by Application, 2020-2025, 2026-2031 ($ millions)
Global Innovative Biologics and Biosimilars market segment percentages, by Application, 2024 (%)
Hospital
Retail Pharmacy
Other
Global Innovative Biologics and Biosimilars market, by region and country, 2020-2025, 2026-2031 ($ millions)
Global Innovative Biologics and Biosimilars market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Innovative Biologics and Biosimilars revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Innovative Biologics and Biosimilars revenues share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Outline of Major Chapters:
Chapter 1: Introduces the definition of Innovative Biologics and Biosimilars, market overview.
Chapter 2: Global Innovative Biologics and Biosimilars market size in revenue.
Chapter 3: Detailed analysis of Innovative Biologics and Biosimilars company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Innovative Biologics and Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Innovative Biologics and Biosimilars Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Innovative Biologics and Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Innovative Biologics and Biosimilars Overall Market Size
2.1 Global Innovative Biologics and Biosimilars Market Size: 2024 VS 2031
2.2 Global Innovative Biologics and Biosimilars Market Size, Prospects & Forecasts: 2020-2031
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Innovative Biologics and Biosimilars Players in Global Market
3.2 Top Global Innovative Biologics and Biosimilars Companies Ranked by Revenue
3.3 Global Innovative Biologics and Biosimilars Revenue by Companies
3.4 Top 3 and Top 5 Innovative Biologics and Biosimilars Companies in Global Market, by Revenue in 2024
3.5 Global Companies Innovative Biologics and Biosimilars Product Type
3.6 Tier 1, Tier 2, and Tier 3 Innovative Biologics and Biosimilars Players in Global Market
3.6.1 List of Global Tier 1 Innovative Biologics and Biosimilars Companies
3.6.2 List of Global Tier 2 and Tier 3 Innovative Biologics and Biosimilars Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global Innovative Biologics and Biosimilars Market Size Markets, 2024 & 2031
4.1.2 Monoclonal Antibodies
4.1.3 Interferon
4.1.4 Insulin
4.1.5 Vaccines
4.1.6 Others
4.2 Segmentation by Type - Global Innovative Biologics and Biosimilars Revenue & Forecasts
4.2.1 Segmentation by Type - Global Innovative Biologics and Biosimilars Revenue, 2020-2025
4.2.2 Segmentation by Type - Global Innovative Biologics and Biosimilars Revenue, 2026-2031
4.2.3 Segmentation by Type - Global Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global Innovative Biologics and Biosimilars Market Size, 2024 & 2031
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 Segmentation by Application - Global Innovative Biologics and Biosimilars Revenue & Forecasts
5.2.1 Segmentation by Application - Global Innovative Biologics and Biosimilars Revenue, 2020-2025
5.2.2 Segmentation by Application - Global Innovative Biologics and Biosimilars Revenue, 2026-2031
5.2.3 Segmentation by Application - Global Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
6 Sights by Region
6.1 By Region - Global Innovative Biologics and Biosimilars Market Size, 2024 & 2031
6.2 By Region - Global Innovative Biologics and Biosimilars Revenue & Forecasts
6.2.1 By Region - Global Innovative Biologics and Biosimilars Revenue, 2020-2025
6.2.2 By Region - Global Innovative Biologics and Biosimilars Revenue, 2026-2031
6.2.3 By Region - Global Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
6.3 North America
6.3.1 By Country - North America Innovative Biologics and Biosimilars Revenue, 2020-2031
6.3.2 United States Innovative Biologics and Biosimilars Market Size, 2020-2031
6.3.3 Canada Innovative Biologics and Biosimilars Market Size, 2020-2031
6.3.4 Mexico Innovative Biologics and Biosimilars Market Size, 2020-2031
6.4 Europe
6.4.1 By Country - Europe Innovative Biologics and Biosimilars Revenue, 2020-2031
6.4.2 Germany Innovative Biologics and Biosimilars Market Size, 2020-2031
6.4.3 France Innovative Biologics and Biosimilars Market Size, 2020-2031
6.4.4 U.K. Innovative Biologics and Biosimilars Market Size, 2020-2031
6.4.5 Italy Innovative Biologics and Biosimilars Market Size, 2020-2031
6.4.6 Russia Innovative Biologics and Biosimilars Market Size, 2020-2031
6.4.7 Nordic Countries Innovative Biologics and Biosimilars Market Size, 2020-2031
6.4.8 Benelux Innovative Biologics and Biosimilars Market Size, 2020-2031
6.5 Asia
6.5.1 By Region - Asia Innovative Biologics and Biosimilars Revenue, 2020-2031
6.5.2 China Innovative Biologics and Biosimilars Market Size, 2020-2031
6.5.3 Japan Innovative Biologics and Biosimilars Market Size, 2020-2031
6.5.4 South Korea Innovative Biologics and Biosimilars Market Size, 2020-2031
6.5.5 Southeast Asia Innovative Biologics and Biosimilars Market Size, 2020-2031
6.5.6 India Innovative Biologics and Biosimilars Market Size, 2020-2031
6.6 South America
6.6.1 By Country - South America Innovative Biologics and Biosimilars Revenue, 2020-2031
6.6.2 Brazil Innovative Biologics and Biosimilars Market Size, 2020-2031
6.6.3 Argentina Innovative Biologics and Biosimilars Market Size, 2020-2031
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Innovative Biologics and Biosimilars Revenue, 2020-2031
6.7.2 Turkey Innovative Biologics and Biosimilars Market Size, 2020-2031
6.7.3 Israel Innovative Biologics and Biosimilars Market Size, 2020-2031
6.7.4 Saudi Arabia Innovative Biologics and Biosimilars Market Size, 2020-2031
6.7.5 UAE Innovative Biologics and Biosimilars Market Size, 2020-2031
7 Companies Profiles
7.1 Roche
7.1.1 Roche Corporate Summary
7.1.2 Roche Business Overview
7.1.3 Roche Innovative Biologics and Biosimilars Major Product Offerings
7.1.4 Roche Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.1.5 Roche Key News & Latest Developments
7.2 Amgen
7.2.1 Amgen Corporate Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Innovative Biologics and Biosimilars Major Product Offerings
7.2.4 Amgen Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.2.5 Amgen Key News & Latest Developments
7.3 AbbVie
7.3.1 AbbVie Corporate Summary
7.3.2 AbbVie Business Overview
7.3.3 AbbVie Innovative Biologics and Biosimilars Major Product Offerings
7.3.4 AbbVie Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.3.5 AbbVie Key News & Latest Developments
7.4 Sanofi
7.4.1 Sanofi Corporate Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Innovative Biologics and Biosimilars Major Product Offerings
7.4.4 Sanofi Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.4.5 Sanofi Key News & Latest Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Corporate Summary
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Innovative Biologics and Biosimilars Major Product Offerings
7.5.4 Johnson & Johnson Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.5.5 Johnson & Johnson Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Corporate Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Innovative Biologics and Biosimilars Major Product Offerings
7.6.4 Pfizer Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.6.5 Pfizer Key News & Latest Developments
7.7 Novo Nordisk
7.7.1 Novo Nordisk Corporate Summary
7.7.2 Novo Nordisk Business Overview
7.7.3 Novo Nordisk Innovative Biologics and Biosimilars Major Product Offerings
7.7.4 Novo Nordisk Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.7.5 Novo Nordisk Key News & Latest Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Corporate Summary
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Innovative Biologics and Biosimilars Major Product Offerings
7.8.4 Eli Lilly Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.8.5 Eli Lilly Key News & Latest Developments
7.9 Novartis
7.9.1 Novartis Corporate Summary
7.9.2 Novartis Business Overview
7.9.3 Novartis Innovative Biologics and Biosimilars Major Product Offerings
7.9.4 Novartis Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.9.5 Novartis Key News & Latest Developments
7.10 Merck
7.10.1 Merck Corporate Summary
7.10.2 Merck Business Overview
7.10.3 Merck Innovative Biologics and Biosimilars Major Product Offerings
7.10.4 Merck Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.10.5 Merck Key News & Latest Developments
7.11 Biogen
7.11.1 Biogen Corporate Summary
7.11.2 Biogen Business Overview
7.11.3 Biogen Innovative Biologics and Biosimilars Major Product Offerings
7.11.4 Biogen Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.11.5 Biogen Key News & Latest Developments
7.12 Celltrion
7.12.1 Celltrion Corporate Summary
7.12.2 Celltrion Business Overview
7.12.3 Celltrion Innovative Biologics and Biosimilars Major Product Offerings
7.12.4 Celltrion Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.12.5 Celltrion Key News & Latest Developments
7.13 Sobi
7.13.1 Sobi Corporate Summary
7.13.2 Sobi Business Overview
7.13.3 Sobi Innovative Biologics and Biosimilars Major Product Offerings
7.13.4 Sobi Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.13.5 Sobi Key News & Latest Developments
7.14 3SBIO
7.14.1 3SBIO Corporate Summary
7.14.2 3SBIO Business Overview
7.14.3 3SBIO Innovative Biologics and Biosimilars Major Product Offerings
7.14.4 3SBIO Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.14.5 3SBIO Key News & Latest Developments
7.15 Changchun High Tech
7.15.1 Changchun High Tech Corporate Summary
7.15.2 Changchun High Tech Business Overview
7.15.3 Changchun High Tech Innovative Biologics and Biosimilars Major Product Offerings
7.15.4 Changchun High Tech Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.15.5 Changchun High Tech Key News & Latest Developments
7.16 Kanghong Pharma
7.16.1 Kanghong Pharma Corporate Summary
7.16.2 Kanghong Pharma Business Overview
7.16.3 Kanghong Pharma Innovative Biologics and Biosimilars Major Product Offerings
7.16.4 Kanghong Pharma Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.16.5 Kanghong Pharma Key News & Latest Developments
7.17 Innovent Biologics
7.17.1 Innovent Biologics Corporate Summary
7.17.2 Innovent Biologics Business Overview
7.17.3 Innovent Biologics Innovative Biologics and Biosimilars Major Product Offerings
7.17.4 Innovent Biologics Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.17.5 Innovent Biologics Key News & Latest Developments
7.18 Gan&Lee
7.18.1 Gan&Lee Corporate Summary
7.18.2 Gan&Lee Business Overview
7.18.3 Gan&Lee Innovative Biologics and Biosimilars Major Product Offerings
7.18.4 Gan&Lee Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.18.5 Gan&Lee Key News & Latest Developments
7.19 Tonghua Dongbao
7.19.1 Tonghua Dongbao Corporate Summary
7.19.2 Tonghua Dongbao Business Overview
7.19.3 Tonghua Dongbao Innovative Biologics and Biosimilars Major Product Offerings
7.19.4 Tonghua Dongbao Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.19.5 Tonghua Dongbao Key News & Latest Developments
7.20 United Laboratory
7.20.1 United Laboratory Corporate Summary
7.20.2 United Laboratory Business Overview
7.20.3 United Laboratory Innovative Biologics and Biosimilars Major Product Offerings
7.20.4 United Laboratory Innovative Biologics and Biosimilars Revenue in Global Market (2020-2025)
7.20.5 United Laboratory Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Innovative Biologics and Biosimilars Market Opportunities & Trends in Global Market
Table 2. Innovative Biologics and Biosimilars Market Drivers in Global Market
Table 3. Innovative Biologics and Biosimilars Market Restraints in Global Market
Table 4. Key Players of Innovative Biologics and Biosimilars in Global Market
Table 5. Top Innovative Biologics and Biosimilars Players in Global Market, Ranking by Revenue (2024)
Table 6. Global Innovative Biologics and Biosimilars Revenue by Companies, (US$, Mn), 2020-2025
Table 7. Global Innovative Biologics and Biosimilars Revenue Share by Companies, 2020-2025
Table 8. Global Companies Innovative Biologics and Biosimilars Product Type
Table 9. List of Global Tier 1 Innovative Biologics and Biosimilars Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Innovative Biologics and Biosimilars Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segmentation by Type – Global Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2024 & 2031
Table 12. Segmentation by Type - Global Innovative Biologics and Biosimilars Revenue (US$, Mn), 2020-2025
Table 13. Segmentation by Type - Global Innovative Biologics and Biosimilars Revenue (US$, Mn), 2026-2031
Table 14. Segmentation by Application– Global Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2024 & 2031
Table 15. Segmentation by Application - Global Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2025
Table 16. Segmentation by Application - Global Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2026-2031
Table 17. By Region– Global Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2024 & 2031
Table 18. By Region - Global Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2025
Table 19. By Region - Global Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2026-2031
Table 20. By Country - North America Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2025
Table 21. By Country - North America Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2026-2031
Table 22. By Country - Europe Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2025
Table 23. By Country - Europe Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2026-2031
Table 24. By Region - Asia Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2025
Table 25. By Region - Asia Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2026-2031
Table 26. By Country - South America Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2025
Table 27. By Country - South America Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2026-2031
Table 28. By Country - Middle East & Africa Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2025
Table 29. By Country - Middle East & Africa Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2026-2031
Table 30. Roche Corporate Summary
Table 31. Roche Innovative Biologics and Biosimilars Product Offerings
Table 32. Roche Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 33. Roche Key News & Latest Developments
Table 34. Amgen Corporate Summary
Table 35. Amgen Innovative Biologics and Biosimilars Product Offerings
Table 36. Amgen Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 37. Amgen Key News & Latest Developments
Table 38. AbbVie Corporate Summary
Table 39. AbbVie Innovative Biologics and Biosimilars Product Offerings
Table 40. AbbVie Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 41. AbbVie Key News & Latest Developments
Table 42. Sanofi Corporate Summary
Table 43. Sanofi Innovative Biologics and Biosimilars Product Offerings
Table 44. Sanofi Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 45. Sanofi Key News & Latest Developments
Table 46. Johnson & Johnson Corporate Summary
Table 47. Johnson & Johnson Innovative Biologics and Biosimilars Product Offerings
Table 48. Johnson & Johnson Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 49. Johnson & Johnson Key News & Latest Developments
Table 50. Pfizer Corporate Summary
Table 51. Pfizer Innovative Biologics and Biosimilars Product Offerings
Table 52. Pfizer Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 53. Pfizer Key News & Latest Developments
Table 54. Novo Nordisk Corporate Summary
Table 55. Novo Nordisk Innovative Biologics and Biosimilars Product Offerings
Table 56. Novo Nordisk Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 57. Novo Nordisk Key News & Latest Developments
Table 58. Eli Lilly Corporate Summary
Table 59. Eli Lilly Innovative Biologics and Biosimilars Product Offerings
Table 60. Eli Lilly Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 61. Eli Lilly Key News & Latest Developments
Table 62. Novartis Corporate Summary
Table 63. Novartis Innovative Biologics and Biosimilars Product Offerings
Table 64. Novartis Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 65. Novartis Key News & Latest Developments
Table 66. Merck Corporate Summary
Table 67. Merck Innovative Biologics and Biosimilars Product Offerings
Table 68. Merck Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 69. Merck Key News & Latest Developments
Table 70. Biogen Corporate Summary
Table 71. Biogen Innovative Biologics and Biosimilars Product Offerings
Table 72. Biogen Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 73. Biogen Key News & Latest Developments
Table 74. Celltrion Corporate Summary
Table 75. Celltrion Innovative Biologics and Biosimilars Product Offerings
Table 76. Celltrion Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 77. Celltrion Key News & Latest Developments
Table 78. Sobi Corporate Summary
Table 79. Sobi Innovative Biologics and Biosimilars Product Offerings
Table 80. Sobi Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 81. Sobi Key News & Latest Developments
Table 82. 3SBIO Corporate Summary
Table 83. 3SBIO Innovative Biologics and Biosimilars Product Offerings
Table 84. 3SBIO Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 85. 3SBIO Key News & Latest Developments
Table 86. Changchun High Tech Corporate Summary
Table 87. Changchun High Tech Innovative Biologics and Biosimilars Product Offerings
Table 88. Changchun High Tech Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 89. Changchun High Tech Key News & Latest Developments
Table 90. Kanghong Pharma Corporate Summary
Table 91. Kanghong Pharma Innovative Biologics and Biosimilars Product Offerings
Table 92. Kanghong Pharma Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 93. Kanghong Pharma Key News & Latest Developments
Table 94. Innovent Biologics Corporate Summary
Table 95. Innovent Biologics Innovative Biologics and Biosimilars Product Offerings
Table 96. Innovent Biologics Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 97. Innovent Biologics Key News & Latest Developments
Table 98. Gan&Lee Corporate Summary
Table 99. Gan&Lee Innovative Biologics and Biosimilars Product Offerings
Table 100. Gan&Lee Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 101. Gan&Lee Key News & Latest Developments
Table 102. Tonghua Dongbao Corporate Summary
Table 103. Tonghua Dongbao Innovative Biologics and Biosimilars Product Offerings
Table 104. Tonghua Dongbao Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 105. Tonghua Dongbao Key News & Latest Developments
Table 106. United Laboratory Corporate Summary
Table 107. United Laboratory Innovative Biologics and Biosimilars Product Offerings
Table 108. United Laboratory Innovative Biologics and Biosimilars Revenue (US$, Mn) & (2020-2025)
Table 109. United Laboratory Key News & Latest Developments
List of Figures
Figure 1. Innovative Biologics and Biosimilars Product Picture
Figure 2. Innovative Biologics and Biosimilars Segment by Type in 2024
Figure 3. Innovative Biologics and Biosimilars Segment by Application in 2024
Figure 4. Global Innovative Biologics and Biosimilars Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Innovative Biologics and Biosimilars Market Size: 2024 VS 2031 (US$, Mn)
Figure 7. Global Innovative Biologics and Biosimilars Revenue: 2020-2031 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by Innovative Biologics and Biosimilars Revenue in 2024
Figure 9. Segmentation by Type – Global Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2024 & 2031
Figure 10. Segmentation by Type - Global Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
Figure 11. Segmentation by Application – Global Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2024 & 2031
Figure 12. Segmentation by Application - Global Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
Figure 13. By Region - Global Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
Figure 14. By Country - North America Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
Figure 15. United States Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 16. Canada Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 17. Mexico Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 18. By Country - Europe Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
Figure 19. Germany Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 20. France Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 21. U.K. Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 22. Italy Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 23. Russia Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 24. Nordic Countries Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 25. Benelux Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 26. By Region - Asia Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
Figure 27. China Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 28. Japan Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 29. South Korea Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 30. Southeast Asia Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 31. India Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 32. By Country - South America Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
Figure 33. Brazil Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 34. Argentina Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 35. By Country - Middle East & Africa Innovative Biologics and Biosimilars Revenue Market Share, 2020-2031
Figure 36. Turkey Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 37. Israel Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 38. Saudi Arabia Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 39. UAE Innovative Biologics and Biosimilars Revenue, (US$, Mn), 2020-2031
Figure 40. Roche Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 41. Amgen Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 42. AbbVie Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 43. Sanofi Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 44. Johnson & Johnson Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 45. Pfizer Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 46. Novo Nordisk Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 47. Eli Lilly Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 48. Novartis Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 49. Merck Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 50. Biogen Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 51. Celltrion Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 52. Sobi Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 53. 3SBIO Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 54. Changchun High Tech Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 55. Kanghong Pharma Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 56. Innovent Biologics Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 57. Gan&Lee Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 58. Tonghua Dongbao Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 59. United Laboratory Innovative Biologics and Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
